Synthetic Biologics Inc (SYN) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Synthetic Biologics Inc (NYSEMKT:SYN) issued its earnings results on Wednesday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10), Bloomberg Earnings reports.

COPYRIGHT VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS” was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/02/synthetic-biologics-inc-syn-issues-quarterly-earnings-results-misses-expectations-by-0-10-eps.html.

SYN has been the topic of several recent analyst reports. Zacks Investment Research downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine downgraded Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $3.92.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Earnings History for Synthetic Biologics (NYSEMKT:SYN)

What are top analysts saying about Synthetic Biologics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Synthetic Biologics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit